Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | CNR1 | P21554 | 10/20 | 0.52 |
| ▸ | CNR2 | P34972 | 10/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6698300 | 0.98 | HTT (0.52) | HTTNPSR1GAACNR1CNR2 | |
| SCHEMBL6696311 | 0.90 | HTT (0.52) | HTTNPSR1GAACNR1CNR2 | |
| SCHEMBL6700073 | 0.89 | HTT (0.51) | HTTNPSR1GAACNR1CNR2 | |
| SCHEMBL6699722 | 0.88 | HTT (0.50) | HTTNPSR1GAACNR1CNR2 | |
| SCHEMBL6686297 | 0.86 | HTT (0.55) | HTTNPSR1GAACNR1CNR2 | |
| SCHEMBL6697663 | 0.86 | ALDH1A1 (0.49) | GAAALDH1A1KMT2AHPGDKDM4E | |
| SCHEMBL6702360 | 0.86 | HTT (0.48) | HTTNPSR1GAACNR1CNR2 | |
| SCHEMBL6698133 | 0.83 | GAA (0.47) | HTTNPSR1GAACNR1CNR2 | |
| SCHEMBL6700551 | 0.83 | HTT (0.52) | HTTNPSR1GAACNR1CNR2 | |
| SCHEMBL6699286 | 0.82 | NPC1 (0.44) | HTTNPSR1GAACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235855-A1 | Phospholipase C inhibitors for use in treating inflammatory disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-11-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235855-A1 | Phospholipase C inhibitors for use in treating inflammatory disorders | PLA2G4C, PLA2G4B, PLA2G5 | HTT 4808/4885NPSR1 891/4885GAA 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.